2030, Drug Development and Trials - Drug Discovery Digest

The Long Road to End Tuberculosis

Codon

NOVEMBER 3, 2024

But they will need to do so if they want to meet the goals set out by the End TB Strategy , namely, to reduce TB cases by 80 percent and curb deaths by 90 percent before 2030. As an undergraduate biology student, I spent some time in a TB lab working on antibiotic resistance — a growing concern for drug developers.

Vaccine

Vaccine Trials Therapies Treatment

Targeting HER3 – a little wave of drug development that’s about to get a lot bigger

SugarCone Biotech

JULY 6, 2025

It follows that HER3-targeting therapies have emerged as a class of anti-cancer treatments designed to treat various tumors that have developed resistance to EGFR or HER2-directed therapies or have emerged due to a NRG1 gene fusion. This is an active drug development landscape with a lot of recent news.

Drug Development

Drug Development Drugs Clinical Trials Therapies

Best-in-Class Solutions Accelerate Development of GLP-1 Therapeutics

PPD

APRIL 14, 2025

This expansion is creating opportunities for clinical trials related to a range of new therapy areas and their subpopulations. The SELECT trial set out to understand whether the drug has similar effect on patients without diabetes.

Clinical Trials

Clinical Trials Trials Clinical Development Disease

Sentiment & Themes Emerging From JPM 2024

LifeSciVC

JANUARY 16, 2024

These are incredible forecasts and CAGRs, which if we assume directionally correct, rely not only on steady growth for approved therapies but also a substantial success rate of, and continued investment in, the development pipeline. Additional trials (e.g.,

Small Molecule

Small Molecule Trials Therapies Disease

The Race for Ozempic Alternatives: Unlocking the Future of Weight Loss Medication

DrugBank

MARCH 7, 2024

As we step into 2024, the momentum is expected to continue, with analysts projecting the weight loss drug market to reach remarkable heights, potentially hitting $100 billion by the end of the decade. adults using obesity medications by 2030, further underlining the growing significance of this sector.

Pharmaceutical Companies

Pharmaceutical Companies Pharmaceuticals Clinical Trials Therapies

What is the role of a CRO in a clinical trial?

Vial

FEBRUARY 8, 2024

To advance new therapies, pharmaceutical, biotech, and medical device companies engage contract research organizations (CROs) for their know-how in navigating the complex landscape of drug development and regulatory pathways and to run clinical trials.

Clinical Trials

Clinical Trials Trials Clinical Research Research

Distinguishing the Roles of Preclinical vs. Clinical CROs in Clinical Research

Vial

MAY 20, 2024

Distinguishing the Roles of Preclinical vs. Clinical CROs in Clinical Research Randomized clinical trials are the gold-standard of evidence-based medicine, representing the culmination of the long, arduous drug development pipeline. billion by 2030 at a compound annual growth rate (CAGR) of 7.5% over this period.

Clinical Research

Clinical Research Clinical Trials Research Trials

ISSUE NO. 43 — Advancing Vision Care With Formulation and Manufacture of Ocular Therapeutics

Alta Sciences

APRIL 8, 2025

Precedence Research reports that the global ophthalmic drug market size is estimated to double in 10 years, from $34.6 billion by 2030. The development of pharmacological interventions for many of these conditions has been accelerating, supported by new delivery methods and formulation approaches.

Clinical Trials

Clinical Trials Nurses Trials Compliance

Why Do Pharma Companies Outsource to CROs?

Vial

FEBRUARY 15, 2024

Clinical trials play a crucial role in advancing medical breakthroughs, but effective management is essential to unlock their full potential. Pharmaceutical companies often face challenges in conducting clinical trials due to the need for substantial knowledge, time, and resources. over the forecast period (2022-2030).

Pharma Companies

Pharma Companies Clinical Trials Compliance Trials

Updates in the Ophthalmology Clinical Landscape

Vial

APRIL 18, 2024

Market research indicates significant growth in the ophthalmic clinical trials market, driven by increased disease prevalence, demand for ocular treatments, and rising research funding. Specifically, the global ophthalmic clinical trials market, valued at USD 1.5 from 2023 to 2030. Dr. Stephen McLeod, M.D.,

Clinical Trials

Clinical Trials Trials Treatment Clinical Research

The Costs of Working with a CRO

Vial

MARCH 27, 2024

The Costs of Working with a CRO Running clinical trials is an integral part of the pharmaceutical industry, crucial to the development and approval of new drugs and treatments. However, because these trials come with a significant financial burden, sponsor companies are constantly seeking ways to optimize their operations.

Clinical Trials

Clinical Trials Trials International Compliance

The Rise of Artificial Intelligence in Drug Discovery

DrugBank

FEBRUARY 19, 2025

The application of Artificial Intelligence (AI) in drug discovery is rapidly transforming the pharmaceutical industry, offering opportunities to accelerate the identification of novel therapeutic targets, optimize molecule design, and enhance clinical trial efficiency. AI is also enabling clinical trial personalization.

Clinical Trials

Clinical Trials Drugs Trials Treatment

Bayer delivers on medical innovation fueling transformation of pharma business

The Pharma Data

FEBRUARY 21, 2022

At its annual Pharma Media Day 2022, Bayer presented the latest developments in the ongoing transformation of its pharmaceuticals business, which is aimed at delivering long-term, sustainable business growth by bringing forward new options for patients.

Clinical Trials

Clinical Trials Small Molecule Clinical Development Disease

Investment Trends in Pharmaceutical Research

DrugBank

AUGUST 9, 2024

Moreover, the probability of success for a drug candidate entering clinical trials is only around 10%, highlighting the substantial risks involved. This high attrition rate directly results from the scientific and regulatory hurdles that drug candidates must overcome. The market for cardiovascular drugs, valued at 155.6

Pharmaceuticals

Pharmaceuticals Research Pharmaceutical Companies Clinical Trials

Regeneron Reports Third Quarter 2020 Financial and Operating Results

The Pharma Data

NOVEMBER 5, 2020

REGN-COV2 trial in the COVID-19 outpatient setting met primary and key secondary endpoints. Key Pipeline Progress Regeneron has more than 20 product candidates in clinical development, including five marketed products for which it is investigating additional indications. billion versus third quarter 2019. Oncology Program.

Production

Production FDA Trials FDA Approval

Addressing the Challenge of Antibiotic Resistance

DrugBank

NOVEMBER 4, 2024

trillion loss in GDP by 2030 shows the urgency of this crisis. While the demand for novel antibiotics is undeniable, the industry still struggles with the harsh realities of antibiotic drug development. This costly, high-risk development pipeline has high attrition rates and uncertain market returns.

Pharmaceutical Companies

Pharmaceutical Companies Pharmaceuticals Government DNA

Five Key Trends Shaping Biopharma and Biotech in 2025

PPD

JANUARY 21, 2025

However, amid this progress, the complexities of drug development have never been more apparent. Food and Drug Administration (FDA) approved 38 new molecular entities for therapeutic use, a decline from 47 in the previous year. In 2024, the U.S. The data revealed five key trends poised to shape biopharma and biotech in 2025.

Clinical Trials

Clinical Trials Trials Clinical Research Drug Development

Drug Discovery Digest

The Long Road to End Tuberculosis

Targeting HER3 – a little wave of drug development that’s about to get a lot bigger

Trending Sources

Best-in-Class Solutions Accelerate Development of GLP-1 Therapeutics

Sentiment & Themes Emerging From JPM 2024

The Race for Ozempic Alternatives: Unlocking the Future of Weight Loss Medication

What is the role of a CRO in a clinical trial?

Distinguishing the Roles of Preclinical vs. Clinical CROs in Clinical Research

ISSUE NO. 43 — Advancing Vision Care With Formulation and Manufacture of Ocular Therapeutics

Why Do Pharma Companies Outsource to CROs?

Updates in the Ophthalmology Clinical Landscape

The Costs of Working with a CRO

The Rise of Artificial Intelligence in Drug Discovery

Bayer delivers on medical innovation fueling transformation of pharma business

Investment Trends in Pharmaceutical Research

Regeneron Reports Third Quarter 2020 Financial and Operating Results

Addressing the Challenge of Antibiotic Resistance

Five Key Trends Shaping Biopharma and Biotech in 2025

Stay Connected